Ultime notizie per MAIA Biotechnology (AMEX:MAIA) Azioni

MAIA Biotechnology

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Mark Cuban and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk <a href="https://www.benzinga.com/general/social-media/24/12/42566461/mark-cuban-says-this-is-the-holy-grail-that-makes-bluesky-better-than-musks-x-platform">may not agree on everything </a>these days, except, perhaps, the potential for a viable third political party. But one thing they do share is the number of people who admire them.
What Happened: Musk and Cuban are both examples of <a href="https://www.benzinga.com/news/education/25/06/46157568/happy-birthday-elon-musk-54-facts-and-figures-about-tesla-spacex-ceo-on-his-54th-birthday">the entrepreneurial spirit</a> that Americans can use to achieve great things through hard work and perseverance, such as creating businesses and becoming extremely wealthy.
While Musk and Cuban created companies in different sectors, they share several commonalities, such as rewarding loyal early employees and adopting a hands-on management style.
The similarities and success could be why Musk and Cuban scored so well in a recent Benzinga poll asking about who would be the best business mentor. The other options in the poll were NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang, Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg and Amazon.com Inc founder Jeff Bezos.
"Of the following, who would you be most likely to pick as your business mentor?" Benzinga asked.
The results were:
<ul class="wp-block-list">
<li>Elon Musk: 36%</li>
<li>Mark Cuban: 30%</li>
<li>Jensen Huang: 23%</li>
<li>Mark Zuckerberg: 8%</li>
<li>Jeff Bezos: 3%</li>
</ul>
The poll found that Musk was the top choice for a potential business mentor — a result likely tied to his reputation as the world's richest person and his relentless work ethic, which often involves sacrificing sleep to focus on his ventures.
Ranking second was Cuban with 30% of the vote. Cuban has been someone that investors and entrepreneurs have looked up to for years thanks to his appearances on "Shark Tank" and being very public with his ownership and running of the NBA's Dallas Mavericks.
Huang ranked third — a testament to the success he's achieved at Nvidia, the company he famously co-founded in a Denny's booth.
Zuckerberg and Bezos scored the lowest totals in the poll.
You may not be a billionaire like Mark Cuban, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46157351/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-71">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk winning the poll isn't likely a surprise given the huge fandom he has thanks to leadership roles at Tesla, SpaceX, xAI and other companies. Musk is the most followed person on the social media platform X.
These days, Musk is often viewed as one of the best entrepreneurs and visionaries of the last 100 years. While some people may disagree with Musk politically or over ideals, they often respect the work he has done to forever change sectors like electric vehicles, clean energy and space exploration.
Cuban's role on "Shark Tank," which began in season 2 and <a href="https://www.benzinga.com/general/entertainment/24/10/41271567/mark-cuban-reflects-on-shark-tanks-enduring-success-the-american-dream-is-alive-and-well">recently came to an end</a>, has helped him gain millions of fans worldwide and also led to him being one of the most loved sharks on the show.
A <a href="https://www.benzinga.com/general/entertainment/25/03/44522293/shark-tank-poll-reveals-most-polarizing-star-is-it-mark-cuban">recent Benzinga poll</a> found Cuban to be the favorite shark with 40% of the vote. Ironically, he also tied at 32% of the vote with Kevin O'Leary for the least favorite shark.
Similar to Musk, Cuban could be a person that many either hate or love, with no middle ground. Many love Cuban's approach on "Shark Tank" of making quick deals and not giving other sharks time to propose deals. Others likely think it hurts the integrity of the show.
Cuban could be ruthless on "Shark Tank," but also showed a human side, often with deals made for products he didn't know but his daughters did, and making investments in entrepreneurs with good stories and a hard work ethic.
The study was conducted by Benzinga from July 1, 2025, through July 3, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 102 adults.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/06/46042333/elon-musk-paid-1m-for-a-james-bond-car-it-was-found-in-a-100-storage-unit">Elon Musk Paid $1M For A James Bond Car — It Was Found In A $100 Storage Unit</a></li>
</ul>
Image created using pictures from Shutterstock.

Education

Entrepreneurship

Management

Success Stories

Exclusives

General

NVDA

TSLA

Mark Cuban And Elon Musk Have Something In Common Beyond Their Billions

During the last three months, 5 analysts shared their evaluations of Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.4, a high estimate of $18.00, and a low estimate of $11.00. This current average reflects an increase of 20.0% from the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569371_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Certara is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Laaman</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Certara. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Certara compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Certara's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Certara's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CERT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Certara analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Certara's Background</h2>
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
<h3>Certara: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Certara displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.67%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Certara's net margin excels beyond industry benchmarks, reaching 4.47%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Certara's ROE stands out, surpassing industry averages. With an impressive ROE of 0.44%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Certara's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CERT

What Analysts Are Saying About Certara Stock

In the latest quarter, 14 analysts provided ratings for Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1088.0, along with a high estimate of $1225.00 and a low estimate of $975.00. Experiencing a 0.78% decline, the current average is now lower than the previous average price target of $1096.54. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569345_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Costco Wholesale's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1060.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1225.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1110.00</td>
<td>$1115.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1075.00</td>
<td>$1070.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$1042.00</td>
<td>$995.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>David Belinger</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1045.00</td>
<td>$1150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Costco Wholesale. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Costco Wholesale compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Costco Wholesale's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Costco Wholesale's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Costco Wholesale analyst ratings.</a>
<h2>Delving into Costco Wholesale's Background</h2>
Costco operates a membership-based, no-frills retail model predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given its frugal cost structure, the firm is able to price its merchandise below that of competing retailers, driving high sales volume per warehouse and generating strong profits on thin margins. Costco operates over 600 warehouses in the United States and has over 60% share in the domestic warehouse club industry. Internationally, Costco operates about 280 warehouses, primarily in Canada, Mexico, Japan, and the UK.
<h3>Costco Wholesale: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Costco Wholesale's revenue growth over a period of 3M has been noteworthy. As of 31 May, 2025, the company achieved a revenue growth rate of approximately 8.02%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Costco Wholesale's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 3.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Costco Wholesale's ROE stands out, surpassing industry averages. With an impressive ROE of 7.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.56%, the company showcases effective utilization of assets.
Debt Management: Costco Wholesale's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COST

Assessing Costco Wholesale: Insights From 14 Financial Analysts

Analysts' ratings for Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) over the last quarter vary from bullish to bearish, as provided by 33 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">15</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $135.97, a high estimate of $200.00, and a low estimate of $95.00. Observing a downward trend, the current average is 2.57% lower than the prior average price target of $139.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569325_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Advanced Micro Devices by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$152.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ben Reitzes</td>
<td>Melius Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ben Reitzes</td>
<td>Melius Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ruben Roy</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$132.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Sujeeva De Silva</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$144.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$121.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Ruben Roy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$132.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$135.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Stacy Rasgon</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$126.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Advanced Micro Devices. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Advanced Micro Devices compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Advanced Micro Devices's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Advanced Micro Devices's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Advanced Micro Devices analyst ratings.</a>
<h2>Get to Know Advanced Micro Devices Better</h2>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
<h3>Financial Milestones: Advanced Micro Devices's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Advanced Micro Devices showcased positive performance, achieving a revenue growth rate of 35.9% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Advanced Micro Devices's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 9.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Advanced Micro Devices's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.23%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Advanced Micro Devices's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.01%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Advanced Micro Devices's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Advanced Micro Devices: Insights From 33 Analyst Reviews

Deep-pocketed investors have adopted a bullish approach towards Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 49 extraordinary options activities for Goldman Sachs Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 30% bearish. Among these notable options, 19 are puts, totaling $1,148,551, and 30 are calls, amounting to $2,691,877.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $590.0 to $850.0 for Goldman Sachs Group over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Goldman Sachs Group's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Goldman Sachs Group's whale activity within a strike price range from $590.0 to $850.0 in the last 30 days. 
<h3>Goldman Sachs Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569302_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$34.85</td>
<td>$34.4</td>
<td>$34.65</td>
<td>$715.00</td>
<td>$806.9K</td>
<td align="right">326</td>
<td align="right">263</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$19.6</td>
<td>$19.15</td>
<td>$19.59</td>
<td>$710.00</td>
<td>$385.8K</td>
<td align="right">371</td>
<td align="right">309</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$42.5</td>
<td>$41.85</td>
<td>$41.9</td>
<td>$640.00</td>
<td>$293.3K</td>
<td align="right">9</td>
<td align="right">70</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/25/25</td>
<td>$28.85</td>
<td>$28.25</td>
<td>$28.55</td>
<td>$710.00</td>
<td>$142.7K</td>
<td align="right">84</td>
<td align="right">55</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$25.6</td>
<td>$25.35</td>
<td>$25.35</td>
<td>$850.00</td>
<td>$139.4K</td>
<td align="right">175</td>
<td align="right">56</td>
</tr>
</tbody>
</table>

<h3>About Goldman Sachs Group</h3>
Goldman Sachs is a storied financial institution, founded in 1869 and best known for its role as a leading global investment bank. The firm has a sprawling reach across global financial centers and has been the leading provider of global merger and acquisition advisory services, by revenue, for the past 20 years. Since the global financial crisis, Goldman has expanded its offerings into more stable fee-based businesses like asset and wealth management, which comprised roughly 30% of post-provision revenue at the end of 2024. The bank holding company generates revenue from investment banking, global market making and trading, lending, asset management, wealth management, and a small and declining portfolio of consumer credit card loans.
After a thorough review of the options trading surrounding Goldman Sachs Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Goldman Sachs Group</h3>
<ul>
<li>Trading volume stands at 1,500,404, with GS's price up by 1.08%, positioned at $723.6.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>Professional Analyst Ratings for Goldman Sachs Group</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $653.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Goldman Sachs Group with a target price of $592. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Goldman Sachs Group, maintaining a target price of $715. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Goldman Sachs Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Check Out What Whales Are Doing With Goldman Sachs Group

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target of $179.18, a high estimate of $200.00, and a low estimate of $150.00. Surpassing the previous average price target of $177.00, the current average has increased by 1.23%.
<img src="https://www.benzinga.com/files/images/story/2025/1751569300_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Laaman</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$186.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Matthew Hershenhorn</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Axsome Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Unraveling the Financial Story of Axsome Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Axsome Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 61.95%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -48.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -107.81%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 3.97, Axsome Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXSM

Where Axsome Therapeutics Stands With Analysts

Whales with a lot of money to spend have taken a noticeably bearish stance on Intuitive Surgical.
Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 11% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $138,480 and 6, calls, for a total amount of $256,590.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $500.0 to $580.0 for Intuitive Surgical over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Intuitive Surgical's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Intuitive Surgical's significant trades, within a strike price range of $500.0 to $580.0, over the past month.
<h3>Intuitive Surgical Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569298_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$39.3</td>
<td>$35.4</td>
<td>$37.45</td>
<td>$540.00</td>
<td>$74.9K</td>
<td align="right">179</td>
<td align="right">23</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/22/25</td>
<td>$20.5</td>
<td>$18.1</td>
<td>$18.0</td>
<td>$530.00</td>
<td>$70.2K</td>
<td align="right">0</td>
<td align="right">39</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$19.0</td>
<td>$18.0</td>
<td>$18.0</td>
<td>$535.00</td>
<td>$59.4K</td>
<td align="right">108</td>
<td align="right">34</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$14.9</td>
<td>$12.6</td>
<td>$13.0</td>
<td>$580.00</td>
<td>$42.9K</td>
<td align="right">162</td>
<td align="right">37</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$53.3</td>
<td>$53.2</td>
<td>$53.3</td>
<td>$565.00</td>
<td>$42.6K</td>
<td align="right">7</td>
<td align="right">8</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.
<h3>Current Position of Intuitive Surgical</h3>
<ul>
<li>With a volume of 702,924, the price of ISRG is up 0.72% at $544.47. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 19 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Surgical</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $440.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Deutsche Bank has revised its rating downward to Sell, adjusting the price target to $440. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuitive Surgical with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

ISRG

Intuitive Surgical's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bearish stance on Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WYNN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Wynn Resorts.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 53%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $70,750, and 12, calls, for a total amount of $671,809.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $115.0 for Wynn Resorts over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Wynn Resorts's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Wynn Resorts's whale activity within a strike price range from $70.0 to $115.0 in the last 30 days. 
<h3>Wynn Resorts 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569293_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$19.15</td>
<td>$18.45</td>
<td>$19.0</td>
<td>$100.00</td>
<td>$190.0K</td>
<td>60</td>
<td align="right">100</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$35.4</td>
<td>$34.55</td>
<td>$35.4</td>
<td>$80.00</td>
<td>$106.2K</td>
<td>973</td>
<td align="right">30</td>
</tr>
<tr>
<td>WYNN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$2.97</td>
<td>$2.67</td>
<td>$2.83</td>
<td>$95.00</td>
<td>$70.7K</td>
<td>343</td>
<td align="right">253</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$13.15</td>
<td>$12.4</td>
<td>$13.15</td>
<td>$92.50</td>
<td>$65.7K</td>
<td>1.6K</td>
<td align="right">50</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$1.75</td>
<td>$1.71</td>
<td>$1.71</td>
<td>$110.00</td>
<td>$63.6K</td>
<td>533</td>
<td align="right">447</td>
</tr>
</tbody>
</table>

<h3>About Wynn Resorts</h3>
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and the US, respectively. In 2024, both the US and Macao were each 50% of total EBITDA.
In light of the recent options history for Wynn Resorts, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Wynn Resorts</h3>
<ul>
<li>Trading volume stands at 1,403,097, with WYNN's price up by 1.06%, positioned at $105.79.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Wynn Resorts</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $109.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has revised its rating downward to Overweight, adjusting the price target to $109. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wynn Resorts options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

WYNN

Wynn Resorts's Options Frenzy: What You Need to Know

In the latest quarter, 4 analysts provided ratings for 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average target of $33.0, a high estimate of $44.00, and a low estimate of $25.00. This current average represents a 11.41% decrease from the previous average price target of $37.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569273_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive 4D Molecular Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to 4D Molecular Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of 4D Molecular Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of 4D Molecular Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FDMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on 4D Molecular Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About 4D Molecular Therapeutics</h2>
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
<h3>Key Indicators: 4D Molecular Therapeutics's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: 4D Molecular Therapeutics's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -50.0%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -342657.14%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): 4D Molecular Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -9.79% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): 4D Molecular Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.92%, the company may face hurdles in achieving optimal financial returns.
Debt Management: 4D Molecular Therapeutics's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FDMT

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics

Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Southern Copper, revealing an average target of $91.88, a high estimate of $105.00, and a low estimate of $79.00. A 4.12% drop is evident in the current average compared to the previous average price target of $95.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569258_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Southern Copper. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodolfo Angele</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.50</td>
</tr>
<tr>
<td>Myles Allsop</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Myles Allsop</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Rodolfo Angele</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.50</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Southern Copper. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Southern Copper compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Southern Copper's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Southern Copper's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SCCO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Southern Copper analyst ratings.</a>
<h2>Unveiling the Story Behind Southern Copper</h2>
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.
<h3>Key Indicators: Southern Copper's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Southern Copper's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 20.08%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Southern Copper's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 30.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Southern Copper's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.1%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Southern Copper's ROA stands out, surpassing industry averages. With an impressive ROA of 4.91%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Southern Copper's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.83, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SCCO

A Glimpse Into The Expert Outlook On Southern Copper Through 4 Analysts

Gold Fields's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) short percent of float has risen 33.82% since its last report. The company recently reported that it has 6.44 million shares sold short, which is 0.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Gold Fields Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gold Fields has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gold Fields's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Gold Fields's peer group average for short interest as a percentage of float is 4.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About Gold Fields?

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 47.37% since its last report. The company recently reported that it has 4.13 million shares sold short, which is 5.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569226_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 5.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Tenet Healthcare?

Fox's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NYSE">FOX</a>) short percent of float has risen 12.88% since its last report. The company recently reported that it has 3.93 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Fox Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fox has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Fox's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Fox's peer group average for short interest as a percentage of float is 6.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Fox?

In the current session, the stock is trading at $44.57, after a 0.22% increase. Over the past month, Hilton Grand Vacations Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) stock increased by 14.94%, and in the past year, by 14.97%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1751569221_0.png" alt="Past Year Chart" />

<h3>Hilton Grand Vacations P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Hilton Grand Vacations has a better P/E ratio of 138.97 than the aggregate P/E ratio of 29.3 of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that Hilton Grand Vacations Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751569221_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

A Look Into Hilton Grand Vacations Inc's Price Over Earnings

Offerings

ALMS

Alumis Files For Mixed Shelf Offering Of Up To $400M

Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) continues to consolidate on Thursday. This comes after the stock <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46248538/bitcoin-ethereum-solana-treasury-companies-need-to-manage-market-volatility-franklin-templeton-report-warns">gained about 35% in just two weeks</a>.
A flag pattern formed on the chart and could be a bullish dynamic. It is why Coinbase is the Stock of the Day.
Some people think technical analysis is like astrology or reading tea leaves. And for many analysts, it is. They look for patterns on charts without understanding the price action and trading dynamics that make them form.
If understood and applied correctly, technical analysis is the study of the supply and demand and psychology in a market.
For example, when the leadership of the market is changing, from bulls to bears or bears to bulls, a reversal pattern may appear on a chart. This can be a rounded pattern, a reversal day, a V pattern, or a double or triple top or bottom.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144915/CoinbasGlobal.one_-1024x587.png" alt="" class="wp-image-972565" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144915/CoinbasGlobal.one_-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144915/CoinbasGlobal.one_-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144915/CoinbasGlobal.one_-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144915/CoinbasGlobal.one_.png 1426w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/equities/25/07/46240607/microsoft-slashes-9000-jobs-while-mark-zuckerbergs-meta-poaches-20-million-worth-of-ai-talent-from-openai-investor-warns-of-jealousy-envy-and-helplessness-among-tech-workers-in-silic">Microsoft Slashes 9,000 Jobs While Mark Zuckerberg&#8217;s Meta Poaches $20 Million Worth Of AI Talent From OpenAI: Investor Warns Of &#8216;Jealousy, Envy, And Helplessness&#8217; Among Tech Workers In Silicon Valley</a>
If the leadership changes slowly over an extended period of time the rounded pattern may form. If the change takes place in one day, a reversal day pattern may form. If a stock tests and fails at resistance or support before reversing, it could be a double or triple top or bottom.
A flag pattern is different. It is a continuation pattern. It indicates a break in a trend that will soon get back into gear.
As you can see on the chart, Coinbase made a large and rapid move higher. This resulted in large amounts of volume trading.
Some of the traders who were doing the buying decided that the stock had gotten ahead of itself. They left the market in hopes that the price would go back down so they could finish their buying at lower prices.
As a result of this, the stock traded sideways and the volume diminished. The key to the flag pattern is the lower volume. It is a characteristic of a break in a trend.
There is a good chance Coinbase breaks out of the upside of this pattern and starts to move higher again.
Read Next: • <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46251589/sp500-technical-analysis-rsi-july-2025">The S&amp;P 500 Sank 10% The Last Time This Warning Flashed</a>

Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Technicals

COIN

Stock Of The Day: Classic Flag Pattern In Coinbase?

Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is underperforming its <a target="_blank" href="https://www.benzinga.com/topic/amazon" rel="noreferrer noopener">tech peers in 2025</a>, trailing the broader market amid intensifying competition in artificial intelligence and cloud infrastructure.
While the S&amp;P 500 has gained around 7% year-to-date and the Nasdaq-100 has risen by 9%, Amazon shares are up just under 2%, underwhelming against the backdrop of a high-growth AI cycle.
Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), in contrast, has surged over 19% driven by strong Azure growth and AI integration across products. Microsoft&#8217;s success is partly due to its existing enterprise relationships and strategic AI investments, particularly in OpenAI, which have integrated well with Azure&#8217;s offerings.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/45982631/amazon-ceo-says-generative-ai-will-reduce-total-corporate-workforce" target="_blank" rel="noreferrer noopener">Amazon CEO Says Generative AI Will Reduce Total Corporate Workforce</a>
<h2 class="wp-block-heading">Amazon&#8217;s Expanding Footprint And Its AI Bet</h2>
Amazon, which began as an online bookstore, has grown into a sprawling conglomerate spanning e-commerce, cloud computing, advertising, streaming, and logistics. In the <a target="_blank" href="https://ir.aboutamazon.com/quarterly-results/default.aspx" rel="noreferrer noopener">last five years</a>, Amazon&#8217;s revenue from third-party seller services, advertising, subscription services, and Amazon Web Services (AWS) has all achieved double-digit growth.
AWS, which runs data centers and provides software tools, generated 16-17% of the company&#8217;s revenue in the last three years, accounting for ~60% or more of its operating income. In a bid to solidify its role in the AI infrastructure arms race, Amazon has committed $100 billion to <a target="_blank" href="https://www.benzinga.com/markets/25/02/43550696/amazon-to-pour-nearly-100-billion-into-ai-in-2025-surpassing-microsoft-and-alphabet-andy-jassy-says-cost-of-inference-will-meaningfully-come-down-amid-deepseek-worries" rel="noreferrer noopener">artificial intelligence initiatives for 2025</a>, surpassing Google parent Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) $75 billion and Microsoft&#8217;s $80 billion.
AWS unit CEO Matt Garman <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/05/45702458/amazon-expands-global-data-centers-boosts-access-to-nvidia-ai-chips-for-cloud-customers" rel="noreferrer noopener">told Bloomberg in</a> May that it is rapidly expanding its global server farm footprint and increasing access to Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) latest AI chips. AWS opened a new data center cluster in Mexico in 2025 and is building additional facilities in Chile, New Zealand, Saudi Arabia, and Taiwan.
Garman highlighted the strong demand for AI infrastructure and confirmed that AWS is working with Nvidia to grow its supply of GB200 semiconductors for customer testing. He also welcomed the opportunity to host OpenAI&#8217;s models on AWS.
Brian White of Monness Crespi Hardt emphasized AWS <a href="https://www.benzinga.com/25/03/44488542/amazons-ai-cloud-strategy-to-stay-strong-amid-near-term-turbulence-says-analyst-aws-remains-well-positioned-for-long-term-ai-trends" target="_blank" rel="noreferrer noopener">already benefits from</a> training large language models and expects that momentum to grow. White believes the platform is well-positioned for growth in AI inference, a rapidly expanding segment of the cloud market.
Mark Mahaney of Evercore ISI has named Amazon his top stock pick, citing &#8220;strong AI-driven cloud potential&#8221;. Wedbush&#8217;s Dan Ives noted rising enterprise demand for AI infrastructure, with Amazon among the top hyperscale providers alongside Microsoft and Google.
<h2 class="wp-block-heading">Robotics, Prime, And Profitability</h2>
Cost efficiency also remains in focus. Bank of America analysts estimate that Amazon&#8217;s integration of <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45727360/amazon-analyst-sees-robotics-unlocking-billions-in-savings" target="_blank" rel="noreferrer noopener">robotics and AI</a> could lead to $16 billion in annual cost savings by 2032. The company currently has over 750,000 robots assisting with 75% of customer orders. The company currently has over 750,000 robots assisting with 75% of customer orders.
J.P. Morgan analyst Doug Anmuth identified Amazon Prime as the company&#8217;s most valuable strategic asset. He projected that Amazon is likely to raise the price of Prime membership in 2026, consistent with its historical four-year pricing pattern. Anmuth believes a $20 increase could yield $3 billion in annual revenue, without significantly affecting subscriber retention.
Amazon&#8217;s Prime Day 2025 event is scheduled to begin on July 8 and will run for four days, with deals across more than 35+ categories, including new segments like groceries and travel. Bank of America analyst Justin Post expects tools like Alexa+ and Rufus to drive Prime Day gross merchandise value to $21.4 billion, a 60% increase over the previous year.
<h2 class="wp-block-heading">Market Sentiment</h2>
Amazon.com currently has a <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings" target="_blank" rel="noreferrer noopener">consensus price forecast</a> of $246 based on 39 analyst ratings. The highest forecast came from Tigress Financial, which set a forecast of $305 on May 6, 2025. Raymond James set the lowest forecast at $195 on April 21, 2025. These estimates average out to $246.67, indicating a potential upside of 10.54%.
<h2 class="wp-block-heading">Analyst Views On Microsoft&#8217;s AI Position</h2>
Analysts remain positive on Microsoft&#8217;s <a href="https://www.benzinga.com/markets/tech/25/07/46204491/microsofts-ai-and-cloud-scale-drives-market-beating-returns" target="_blank" rel="noreferrer noopener">long-term prospects</a> in AI. Derrick Wood of TD Cowen said the company is &#8220;well-positioned in key secular growth markets.&#8221; Brad Sills of Bank of America referred to Microsoft as &#8220;the leading AI player in applications and infrastructure.&#8221; Kash Rangan of Goldman Sachs forecast Microsoft Cloud revenue will surpass $300 billion by fiscal 2029, citing its AI pricing strategy. Dan Ives of Wedbush projected Microsoft will reach a $4 trillion market cap this summer and $5 trillion within 18 months, driven by AI momentum.
Price Action: AMZN stock is trading lower by 0.13% to $223.13 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46252229/netflix-is-worth-half-trillion-and-one-analyst-forecasts-trillion-dollar-valuation" target="_blank" rel="noreferrer noopener">Netflix Is Worth Half Trillion And One Analyst Forecasts Trillion Dollar Valuation</a></li>
</ul>
Image via Shutterstock

Movers

Tech

AMZN

GOOG

GOOGL

MSFT

Why Amazon Lags Its Peers In 2025

ReNew Energy Global Plc ("ReNew" or the "Company") today announces that it has received a final non-binding offer dated July 2, 2025, from Abu Dhabi Future Energy Company PJSC-Masdar ("Masdar"), Canada Pension Plan Investment Board ("CPP Investments"), Platinum Hawk C 2019 RSC Limited as trustee for the Platinum Cactus A 2019 Trust ("Platinum Hawk") (a wholly owned subsidiary of the Abu Dhabi Investment Authority, "ADIA") and Sumant Sinha (the Founder, Chairman and CEO of ReNew) (together with Masdar, CPP Investments and Platinum Hawk, the "Consortium") to acquire the entire issued and to be issued share capital of the Company not already owned by members of the Consortium for cash consideration of US$8.00 per share. This represents an increase of US$0.93 per share, equivalent to 13.2%, from the initial non-binding proposal dated December 10, 2024. The final non-binding offer represents a 26.2% premium versus the undisturbed share price of US$6.34 on December 10, 2024, being the closing share price prior to the initial non-binding proposal becoming public and a 38.9% premium to the 30-day volume-weighted average price of US$5.76 per share (as of December 10, 2024).
As previously announced, the ReNew Board of Directors formed a Special Committee ("Special Committee") led by Manoj Singh, the Lead Independent Director, consisting of the six independent non-executive ReNew Directors to consider the proposals received from the Consortium.
The Special Committee is in the process of evaluating the final non-binding offer alongside its independent financial advisor, Rothschild &amp; Co and independent legal counsel, Linklaters LLP. Active discussions with the Consortium remain ongoing and the Special Committee will provide an update to the market as soon as reasonably practicable.
No assurance can be given regarding the likelihood, terms or details of a potential transaction resulting from the final non-binding offer received from the Consortium or any other potential transaction. Further decisions or disclosures by the Special Committee will be made as appropriate or required.

ReNew Energy Confirms It Has Received $8.00/Share Buyout Offer From Consortium; Says The Special Committee Is In The Process Of Evaluating The Final Non-Binding Offer And Will Provide An Update To The Market As Soon As Reasonably Practicable

Major cryptocurrencies are consolidating at recently established highs as sentiment remains upbeat due to strong institutional inflows and rising optimism around spot ETF approvals for altcoins.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$109,701.36</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,579.45</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$151.69</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.26</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1709</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001186</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume decreasing by 4.3% and daily active addresses growing by 2.4%. Transactions greater than $100,000 are up from 11,019 to 12,303 in a single day. Exchanges netflows are up by 19.9%.</li>
<li>Coinglass data reports 88,497 traders were liquidated in the past 24 hours for $242.80 million.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46244196/bitcoin-ethereum-poised-for-bullish-july-experts-say-but-only-one-is-underowned">Bitcoin, Ethereum Poised For Bullish July, Experts Say, But Only One Is &#8216;Underowned&#8217;</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46242838/anthony-scaramucci-predicts-bitcoin-treasury-frenzy-will-fade">Anthony Scaramucci Predicts Bitcoin Treasury Frenzy &#8216;Will Fade&#8217;</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46243544/arthur-hayes-shares-his-stablecoin-play-and-it-isnt-betting-on-circle">Arthur Hayes Shares His &#8216;Stablecoin Play&#8217; — And It Isn&#8217;t Betting On Circle</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46230381/xrp-spikes-3-as-ripple-applies-for-us-banking-license">XRP Spikes 3% As Ripple Applies For US Banking License</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
</tr>
<tr>
<td>Bonk</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>)</td>
<td>$0.00001645</td>
</tr>
<tr>
<td>Fartcoin</td>
<td>(CRYPTO: FARTCOIN)</td>
<td>$1.19</td>
</tr>
<tr>
<td>Celestia</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TIA</a>)</td>
<td>$1.61</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Ted Pillows <a href="https://x.com/TedPillows/status/1940818758723121310">noted</a> that Bitcoin dominance appears set for a short-term decline, likely triggering a brief relief rally for altcoins. While it&#8217;s not expected to mark the beginning of a full altseason, altcoin holders may still enjoy a few weeks of upside.
Byzantine General <a href="https://x.com/ByzGeneral/status/1940813534646227175">sees</a> a breakout in both price and open interest (OI) typically signals continued upside. Based on this pattern, BTC could be heading toward the next target at $112,000.
Titan of Crypto observed that Bitcoin is nearing a crucial mid-channel resistance level on the weekly chart. A breakout above this red mid-range line could pave the way for a move into the higher green target zone.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Approaching the Mid-Channel Line &#x1f534;<a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> is getting closer to the key red mid-range level on the weekly structure. A breakout above could open the path to the green zone &#x1f4c8; <a href="https://t.co/VUFCjQdnIo">pic.twitter.com/VUFCjQdnIo</a>
&mdash; Titan of Crypto (@Washigorira) <a href="https://twitter.com/Washigorira/status/1940792795503251588?ref_src=twsrc%5Etfw">July 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto Mikey stated that with the holiday weekend approaching, this appears to be a good spot to hedge short on Bitcoin. He advises it is time to play it safe and enjoy the break.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Good spot to hedge short into holiday weekend. Hedge enjoyyyeeer <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/fevMNcvWg8">pic.twitter.com/fevMNcvWg8</a>
&mdash; Crypto Mikey (@CryptoCX1) <a href="https://twitter.com/CryptoCX1/status/1940783252085919939?ref_src=twsrc%5Etfw">July 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46249285/bitcoin-ethereum-xrp-need-not-worry-about-summer-blues-as-long-as-this-critical-support-holds-trader-says">Bitcoin, Ethereum, XRP Need Not Worry About Summer Blues As Long As This Critical Support Holds, Trader Says</a></li>
</ul>
Image: Shutterstock

$BONK

$BTC

$DOGE

$ETH

$SHIB

$SOL

$TIA

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Hold Steady Ahead of Holiday Weekend — Ideal Time To Hedge Shorts

Webull Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares are moving lower after the company announced a $1 billion standby equity agreement Thursday <a href="https://www.benzinga.com/pressreleases/25/07/n46251836/webull-announces-1-billion-standby-equity-agreement">after the market close</a>.
What Happened: Webull announced that it secured a financing option through a standby equity purchase agreement with YA II PN, an investment fund managed by Yorkville Advisors.
The agreement gives the company an option to issue up to&nbsp;$1 billion&nbsp;in Class A ordinary shares to Yorkville over a three-year period. Yorkville will pay a 2.5% discount to the market price for any shares issued under the purchase agreement.
Webull said it intends to strategically use the purchase agreement to raise and deploy capital as it needs. 
&#8220;With access to capital available through the Purchase Agreement, Webull is well positioned to pursue new growth opportunities, such as product expansion, new asset classes, and geographic expansion,&#8221; said&nbsp;Anthony Denier, group president and U.S. CEO of Webull. 
&#8220;As we survey the evolving market landscape and consider next-generation technologies in the space such as stable coins and real-world asset tokenization, access to capital will be critical to our ability to innovate and compete on the cutting edge going forward.&#8221;
BULL Price Action: <a href="http://benzinga.com/quote/bull">Webull shares</a> were down 4.27% in after-hours, trading at $13.69 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46248233/robinhood-stock-pulls-back-from-all-time-highs-whats-going-on">Robinhood Stock Pulls Back From All-Time Highs: What&#8217;s Going On?</a></li>
</ul>
Photo: gguy/Shutterstock.com

Financing

BULL

Webull Stock Is Sliding After The Close: What's Going On?

Press Releases

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

MAIA Biotechnology Announces Director Participation in Recent Private Placement

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

MAIA Biotechnology Announces Private Placement of Approximately $669,500

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

MAIA Biotechnology to Present at BIO International Convention 2025

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

MAIA

Noble Capital Markets

Screenshot 2024-09-10 at 8.49.39 PM

Biotech

REGN

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Screenshot 2024-06-06 at 5.43.20 PM

New Clinical Data Reveals MAIA Biotechnology&#39;s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Screenshot 2024-05-21 at 5.35.44 PM

MAIA Biotechnology&#39;s Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

Screenshot 2024-02-28 at 6.41.05 PM

MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer

Comments

MAIA Biotechnology

Notizie

Ultime notizie per MAIA Biotechnology (AMEX:MAIA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO